{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:27:07Z","timestamp":1785518827162,"version":"3.56.0"},"reference-count":44,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T00:00:00Z","timestamp":1620086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2021,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Owing to its heterogeneity and rarity, management of disseminated marginal zone B\u2010cell lymphoma (MZL) remains largely understudied. We present prospective data on choice of systemic treatment and survival of patients with MZL treated in German routine practice. Of 175 patients with MZL who had been documented in the prospective clinical cohort study Tumour Registry Lymphatic Neoplasms (NCT00889798) collecting data on systemic treatment, 58 were classified as extranodal MZL of mucosa\u2010associated lymphoid tissue (MALT) and 117 as non\u2010MALT MZL. We analyzed the most commonly used first\u2010line and second\u2010line chemo(immuno)therapies between 2009 and 2016 and examined objective response rate (ORR), progression\u2010free survival (PFS), overall survival (OS) and prognostic factors for survival. Compared to patients with MALT MZL, those with non\u2010MALT MZL more often presented with bone marrow involvement (43% vs. 14%), Ann Arbor stage III\/IV (72% vs. 57%) and were slightly less often in good general condition (ECOG\u00a0=\u00a00; 41% vs. 47%). In German routine practice, rituximab\u2010bendamustine for a median of 6 cycles was the most frequently used first\u2010line (76%) and second\u2010line treatment (36%), with no major differences between MZL subtypes. The ORR for patients encompassing any positive response was 81%. For patients with MALT and non\u2010MALT MZL, respectively, 5\u2010years PFS was 69% (95% CI 52%\u201381%) and 66% (95% CI 56%\u201375%), 5\u2010years OS 79% (95% CI 65%\u201389%) and 75% (95% CI 66%\u201383%). Cox proportional hazards models showed a significantly increased risk of mortality for higher age in all patient groups. Our prospective real world data give valuable insights into the management and outcome of non\u2010selected patients with MZL requiring systemic treatment and can help optimize therapy recommendations.<\/jats:p>","DOI":"10.1002\/hon.2868","type":"journal-article","created":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T03:17:02Z","timestamp":1620098222000},"page":"313-325","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Rare lymphomas in routine practice \u2013 Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms"],"prefix":"10.1002","volume":"39","author":[{"given":"Wolfgang","family":"Knauf","sequence":"first","affiliation":[{"name":"Centrum f\u00fcr H\u00e4matologie und Onkologie Bethanien  Frankfurt\/Main Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Abenhardt","sequence":"additional","affiliation":[{"name":"Onkologie Gilching  Gilching Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Koenigsmann","sequence":"additional","affiliation":[{"name":"Onkologisches Ambulanzzentrum am Diakovere Henriettenstift gGmbH  Hannover Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Maintz","sequence":"additional","affiliation":[{"name":"Medizinisches Versorgungszentrum West GmbH W\u00fcrselen H\u00e4matologie\u2010Onkologie  W\u00fcrselen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiner","family":"Sandner","sequence":"additional","affiliation":[{"name":"Onkologische Praxis Passau  Passau Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u2010Oliver","family":"Zahn","sequence":"additional","affiliation":[{"name":"Medizinisches Versorgungszentrum Onkologische Kooperation  Goslar Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Schnell","sequence":"additional","affiliation":[{"name":"Praxis Internistischer Onkologie und H\u00e4matologie (PIOH)  Frechen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Tech","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Health Economics iOMEDICO  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Kaiser\u2010Osterhues","sequence":"additional","affiliation":[{"name":"Medical Department iOMEDICO  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonora","family":"Houet","sequence":"additional","affiliation":[{"name":"Medical Department iOMEDICO  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6098-1301","authenticated-orcid":false,"given":"Norbert","family":"Marschner","sequence":"additional","affiliation":[{"name":"Praxis f\u00fcr interdisziplin\u00e4re Onkologie\u00a0&amp; H\u00e4matologie  Freiburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the TLN\u2010Group (Tumour Registry Lymphatic Neoplasms)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-624304"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24086"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.010"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3501-8"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-019-0687-5"},{"key":"e_1_2_11_7_1","first-page":"263","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised","author":"Campo E","year":"2017"},{"key":"e_1_2_11_8_1","first-page":"259","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised","author":"Cook JR","year":"2017"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.09.005"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S133291"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.237990"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.94"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26103"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27773"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.13826.1"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000463"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000351"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000368315"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2139"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3449-8"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2740"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13295"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"e_1_2_11_24_1","volume-title":"The Statistical Analysis of Failure Time Data","author":"Kalbfleisch JD","year":"1980"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.2307\/2530286"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25707"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00605"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)00021-0"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-795302"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15641"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-771915"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3496"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt343"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70455-3"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.065995"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-06-720599"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-747345"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2647"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2773"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33117"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-624296"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2868","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hon.2868","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2868","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T22:23:03Z","timestamp":1693347783000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,4]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["10.1002\/hon.2868"],"URL":"https:\/\/doi.org\/10.1002\/hon.2868","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/HON.2868\/v1\/decision1","asserted-by":"object"}]},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,4]]},"assertion":[{"value":"2021-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}